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Abstract
Background: Uterine sarcomas are very rare malignancies with no approved chemotherapy protocols. Histone
deacetylase (HDAC) inhibitors belong to the most promising groups of compounds for molecular targeting
therapy. Here, we described the antitumor effects of suberoylanilide hydroxamic acid (SAHA; vorinostat) on MES-SA
uterine sarcoma cells in vitro and in vivo. We investigated effects of vorinostat on growth and colony forming
ability by using uterine sarcoma MES-SA cells. We analyzed the influence of vorinostat on expression of different
HDACs, p21WAF1 and activation of apoptosis. Finally, we examined the antitumor effects of vorinostat on uterine
sarcoma in vivo.
Results: Vorinostat efficiently suppressed MES-SA cell growth at a low dosage (3 μM) already after 24 hours
treatment. Decrease of cell survival was even more pronounced after prolonged treatment and reached 9% and
2% after 48 and 72 hours of treatment, respectively. Colony forming capability of MES-SA cells treated with 3 μM
vorinostat for 24 and 48 hours was significantly diminished and blocked after 72 hours. HDACs class I (HDAC2 and
3) as well as class II (HDAC7) were preferentially affected by this treatment. Vorinostat significantly increased
p21WAF1 expression and apoptosis. Nude mice injected with 5 × 106 MES-SA cells were treated for 21 days with
vorinostat (50 mg/kg/day) and, in comparison to placebo group, a tumor growth reduction of more than 50% was
observed. Results obtained by light- and electron-microscopy suggested pronounced activation of apoptosis in
tumors isolated from vorinostat-treated mice.
Conclusions: Our data strongly indicate the high therapeutic potential of vorinostat in uterine sarcomas.
Background
Uterine sarcomas are uncommon, representing approx.
5% of all uterine malignancies [1]. These tumors are
often diagnosed in advanced stages and carry an unfa-
vorable prognosis. The final diagnosis is based upon his-
tological and immunohistochemical analyses of tumor
tissue obtained by biopsy or surgical excision [2]. Due
to the low incidence of uterine sarcomas, data concern-
ing both molecular mechanisms of their pathogenesis
and therapeutic approaches are quite limited and further
information is needed. Since uterine sarcomas are rare,
they are also not uniformly treated. The mechanisms
involved in the tumorigenesis are only in the beginning
of being elucidated. Thus, the establishment of in vivo
systems for basic investigations and testing therapeutic
approaches in uterine sarcomas is particularly impor-
tant. Cell lines originating from these malignancies are
rare and so are in vivo systems. The usefulness of some
uterine sarcoma cell lines is limited by the fact that the
vast majority of them are not tumorigenic in nude mice.
This is also the case for cell lines isolated from low
grade endometrial stromal sarcomas, e.g., ESS-1 cells
[3]. For some other cell lines details regarding tumori-
genicity in nude mice are missing. In a recent publica-
tion Kakuno et al reported the establishment of a new
cell line (OMC-9) originated from a human endometrial
stromal sarcoma [4]. According to the authors, these
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cells are tumorigenic in nude mice and could, therefore,
be useful for development of an in vivo system. Unfortu-
nately, this cell line was not commercially available till
now. Since MES-SA cells established by Harker and
coauthors are tumorigenic in nude mice, we decided to
use them both for in vitro and for in vivo experiments
in order to test the efficacy of suberoylanilide hydroxa-
mic acid (SAHA; vorinostat).
Vorinostat is a potent inhibitor of HDACs class I and
II. These enzymes are responsible for deacetylation of
histones and some other proteins and consequently con-
trol the expression of different regulatory genes which
are responsible for cell growth, proliferation, apoptosis,
autophagy and for regulation of other mechanisms
involved in the tumor development and growth [5-11].
Our recent data, both published and unpublished,
strongly suggest that some HDACs are deregulated in
endometrial stromal sarcomas and other uterine tumors
of mesenchymal origin [12,13]. The therapeutic utility of
vorinostat is supported by the fact that it has been
recently approved by FDA for therapy of cutaneous
T-cell lymphoma. Moreover, vorinostat is used in clini-
cal trials in patients with other solid tumors, such as
mesothelioma, medulloblastoma, prostate and thyroid
cancer [14-16]. Our in vitro and in vivo data suggest
that vorinostat is an active drug potentially suitable for
targeted treatment of uterine sarcomas.
Methods
Chemicals and cell lines
All chemicals and media were purchased from Sigma
(SIGMA-ALDRICH Handels GmbH, Vienna, Austria),
unless otherwise specified. Vorinostat was purchased
from Alexis Biochemicals (Lausen, Switzerland). The
human uterine sarcoma cell line MES-SA, established by
Harker et al [1], was purchased from ATCC (ATCC Nr.
CRL-1976). The original specimen was characterized as
poorly differentiated uterine sarcoma and the cells were
isolated after hysterectomy of a 56 years old Caucasian
woman. It has been also shown that these cells are
highly tumorigenic in nude mice. All experiments were
performed according to local ethical guidelines.
Drug formulation
For in vitro experiments a 10 mM vorinostat stock solu-
tion was prepared with DMSO and stored at -20°C.
Since it is well known that DMSO can cause different
inflammatory reactions when injected intraperitoneally
for a longer period of time, we wanted to avoid this sol-
vent for our in vivo experiments. Therefore, we prepared
a solution of vorinostat in HOP-b-CD (2-hydroxypropyl-
b-cyclodextrin) as already described by Hockly et al
[17]. Briefly, vorinostat was dissolved in 5 molar equiva-
lents of HOP-b-CD in water, it was heated until fully
dissolved, rapidly cooled on ice to room temperature
and stored at -20°C. A fresh solution was prepared every
week and administered to the mice by intraperitoneal
injection in a total volume of approx. 300 μl, so that the
final concentration for each animal was 50 mg/kg/day.
In vivo experiments
The animal experiments were approved by the Austrian
ministry of education and science according to the
regulations for animal experimentation. Athymic Nude-
Foxn1nu/nu mice used in the present study were
purchased from Harlan (Harlan Italy, San Pietro al Nati-
sone, Italy). They were housed at 22°C at a constant
light-dark cycle (12-h light, 12-h dark) and had free
access to water and rodent chow (4-5% fat, 21% protein;
Sniff, Soest, Germany). All animals used in this study
were kept under standardized, pathogen-free living
conditions in the animal facility of our department.
Twelve weeks old male mice (n = 14) were anesthe-
tized with Isofluran (Pharmacia & Upjohn SA, Guyan-
court, France) and 5 × 106 MES-SA cells were injected
subcutaneously into the right flank of the animal. Mice
from a control group received placebo containing 300 μl
of empty HOP-b-CD (2-hydroxypropyl-b-cyclodextrin)
vesicles. Another group of mice received vorinostat
dissolved in HOP-b-CD at a concentration of 50 mg/kg/
day. Both, empty vesicles and vorinostat were adminis-
tered intraperitoneally, starting on the day 4 after the
injection of MES-SA tumor cells. Mice body weight and
tumor size (w2 × l × 0.52; measured by caliper) were
estimated twice a week. All mice were treated for 21
days and afterwards sacrificed by cervical dislocation.
Each tumor was isolated as a whole and different tumor
parameters (weight, volume, size and macroscopic
appearance) were determined. Finally, tumor slices were
cryo preserved and formalin fixed (4%) for further
analyses.
Western blot analysis
Cell lysates were prepared by using RIPA buffer (25 mM
Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS), and the protein concentration
was determined by Bio-Rad DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA). Protein lysates were sepa-
rated by SDS-PAGE and transferred to nitrocellulose
membrane (Bio-Rad). Following antibodies and dilutions
were used: rabbit anti HDAC1 (1 μg/ml) (Labvision, Fre-
mont, CA, USA); rabbit anti HDAC2 (1 μg/ml) (Zymed,
San Francisco, CA, USA); rabbit anti HDAC3 (9 μg/ml)
(Novus biologicals, Littleton, CO, USA); rabbit anti
HDAC7 (3 μg/ml) (Abcam, Cambridge, UK); mouse anti
p21WAF1 (0.5 μg/ml) (Zymed). As secondary antibodies
we used rabbit anti-mouse and swine anti-rabbit HRP-
coupled antibodies at a final concentration of 1 μg/ml
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(DAKO, Copenhagen, Denmark). An overnight incuba-
tion at 4°C was used for all primary antibodies, followed
by washing and 2-hours incubation at RT with second-
ary antibodies. Specific protein bands were visualized by
enhanced chemiluminescence assay (ECL; Amersham
Biosciences, Buckinghamshire, England). To demon-
strate equal loading of protein samples all western blots
were probed for b-tubulin.
Clonogenic assay
MES-SA cells were seeded in ∅ 6 cm culture dishes
(300 cells/dish) and treated with 3 μM vorinostat for 24,
48 and 72 hours. Afterwards fresh medium was added
and the cells were cultured for another 14 days followed
by fixation with butanol:acetic acid (3:1) and staining
with 0.5% crystal violet.
Electron microscopy
Cryo-preserved tumor tissue was fixed with ice-cold glu-
taraldehyde (2.5% in 0.1 M cacodylate buffer, pH 7.4) for
30 minutes. After fixation, the samples were postfixed in
1% OsO4 in the same buffer for 30 min, washed twice
with cacodylate A buffer and rehydrated through series
of increasing alcohol concentrations (70, 80, 90, 95%
ethanol, 10 min each). Tissue was incubated in prophy-
lenoxid - epoxid resin (1:1) for 1 hour and afterwards
with epoxid resin over night at 4°C. Ultrathin sections
were stained with uranyl acetate and lead citrate and
viewed with a Philips CM100 transmission electron
microscope. Photographs were made with Kodak Elec-
tron Image Film SO-163 (Kodak, Vienna, Austria) and
developed following the procedure recommended by
producer.
Apoptosis measurement
MES-SA cells were treated with medium containing 3
μM vorinostat for indicated time periods. After harvest-
ing the cells were fixed in 2% formaldehyde for 10 min
at 37°C, followed by permeabilization with methanol
(90%). Staining was performed by Cleaved Caspase-3
(Asp175) antibody conjugated with Alexa Fluor 488
(Cell Signaling Technology, #9669) for 60 minutes at
room temperature. Measurements were performed on
FACSCalibur™ (BD Biosciences). Staurosporine-treated
cells (1 μM for 4 hours) were used as positive and
untreated MES-SA cells as negative controls.
Statistical analysis
If not stated otherwise, all values represent means of at
least three independent experiments ± SD. Values were
compared using Student’s t test. P ≤ 0.05 was consid-
ered statistically significant.
Results
Vorinostat inhibits cell growth and colony formation
in vitro
In order to examine the most effective vorinostat concen-
tration for growth inhibition of MES-SA uterine sarcoma
cells, we performed cell proliferation experiments by using
[3H]thymidine uptake assay. Five different vorinostat
concentrations (0.5, 1, 3, 5, and 10 μM) were tested over
three time intervals (24, 48, and 72 h). As shown in Fig.
1A, vorinostat concentration as low as 0.5 μM caused
growth inhibition in comparison to untreated, control
MES-SA cells. These effects largely increased with higher
vorinostat concentrations. Considering a dose response
curve, 3 μM vorinostat has been used as a working
concentration for further experiments, this concentration
being in agreement with our previous studies on ESS-1
cells [13]. As shown in Fig. 1B, the growing curve for
MES-SA cells treated with 3 μM vorinostat showed a pro-
minent decrease in comparison to untreated cells. Twenty
four hours after the vorinostat treatment cell number was
decreased to 48% in comparison to untreated cells,
whereas 48 and 72 hours after treatment it was further
decreased to 9% and 2%, respectively. These data clearly
indicate high sensitivity of MES-SA cells to vorinostat.
For colony forming assay, 300 MES-SA cells were
seeded per ∅ 6 cm dish. After the treatment with vori-
nostat for 24, 48 and 72 hours they were grown for
another 14 days and finally stained with crystal violet.
As can be seen in Fig. 1C, there was a pronounced dif-
ference in the colony formation ability between
untreated and treated MES-SA cells. This reduced num-
ber of colonies showed that vorinostat efficiently killed
the cells in a time dependent-manner.
For more general impact of our findings, we addition-
ally compared the MES-SA with ESS-1 endometrial stro-
mal sarcoma cells. This was considered to be of further
importance because no in vivo system for investigation
of endometrial stromal sarcoma has been established
until now. As can be seen in Table 1, these two cell
lines share many similarities regarding the expression of
cell-markers tested in our study. In addition, our pre-
vious data showed that vorinostat efficiently inhibits the
growth of ESS-1 cells in vitro (13).
Vorinostat deregulates expression of HDACs and p21WAF1
We examined the expression of different members of
HDACs class I (HDAC1, 2 and 3) and class II (HDAC7)
in untreated and vorinostat treated MES-SA cells. There
was no difference in the HDAC1 expression in
untreated and treated cells during the whole duration of
treatment (72 hours in total) (Fig. 2A, B). On the other
hand, HDAC2, 3 and 7 showed pronounced inhibition
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of expression by vorinostat. The expression of HDAC2
and HDAC3 was affected already 24 hours after the vor-
inostat treatment, whereas inhibition of HDAC7 was
not detectable until 48 hours after starting the treat-
ment. All effects concerning HDAC 2, 3, and 7 became
even more pronounced after 72 hours of treatment.
The expression of a cyclin-dependent kinase inhibitor
p21WAF1 in vorinostat treated MES-SA cells was signifi-
cantly upregulated already 24 hours after starting the
treatment and continuously increased during the follow-
ing 48 hours. These data are in agreement with previous
results obtained with ESS-1 cells, suggesting a typical
G1 arrest caused by the vorinostat treatment [12].
Figure 1 Vorinostat decreases the growth and colony forming ability of MES-SA cells in vitro. (a) Dose response curve for MES-SA cells
treated with five different vorinostat concentrations over three time periods. Cell proliferation was measured by using [3H]thymidine uptake
assay. Results are expressed as percentage inhibition of [3H]thymidine incorporation upon vorinostat treatment and normalized to untreated
cells. (b) MES-SA cells were treated with 3 μM vorinostat for 24, 48 and 72 hours. Vorinostat induced a strong decrement in the number of
treated cells in comparison to untreated control cells. (c) The ability of colony formation was drastically reduced in vorinostat-treated MES-SA
cells already after 24 hours and continued to decrease in a time-dependent manner.
Table 1 Immunohistochemical characterization of MES-SA








Keratin - + (5-10%; cytoplasmic)
EGFR - +++
-, negative; +, weakly positive; ++, moderately positive; +++, strongly positive
immunohistochemical reaction.
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Vorinostat inhibits tumor growth in xenograft mice
On the fourth day after the subcutaneous injection of
5 × 106 MES-SA cells in all mice a small tumor was
palpable. Thus, we decided to start with the vorinostat
treatment at that time point. Mice were injected with
either placebo (HOP-b-CD) or 50 mg/kg/day vorino-
stat for 5 consecutive days during the week, for 21
days. During the vorinostat treatment the body weight
of all animals was determined twice a week and as
shown in Fig. 3A, remained stable during the whole
treatment period. This suggested that at indicated con-
centration and administration regimen vorinostat was
well tolerated.
After 21 days of treatment the animals were sacrificed
and different organs, i.e. liver, spleen, lung, heart and
intestine, were checked for pathological changes and
tumor metastases. No structural changes were found in
analyzed organs. Tumors were isolated and tumor size,
volume and weight were determined. Most tumors were
encapsulated and well circumscribed. On day 21, there
was a tumorous ulceration in one placebo case.
Although the surface area of the tumor was well sup-
plied with blood vessels, we observed tumors larger then
800 mm3 to be most often necrotic in their center.
However, this can be expected from the rapid tumor










































































































































































































Figure 2 Expression of different histone deacetylases and p21WAF1 in untreated and vorinostat-treated MES-SA cells. (a) Immunoblot
analyses were used to examine the expression of different HDACs from class I (HDAC 1, 2 and 3) and class II (HDAC7). Note that not all HDACs
were equally affected by vorinostat. HDAC2, 3 and 7 were highly deregulated, whereas HDAC1 was not affected. The expression of cyclin-
dependent kinase inhibitor p21WAF1 was highly increased in vorinostat-treated MES-SA cells. (b) Western blot data were quantified
densitometrically and beta-tubulin was used as a loading control.
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Figure 3 Vorinostat suppressed tumor growth in nude mice xenografts. 5 × 106 MES-SA cells were injected subcutaneously in Nude-
Foxn1nu/nu mice (n = 14) and four days later mice were injected either placebo (HOP-b-CD) or 50 mg/kg/day vorinostat dissolved in HOP-b-CD
for a total of 21 days. (a) The mice weight curve was stable during the whole treatment indicating that no cachexy was induced by tumor
growth. (b) Two representative xenograft mice from each placebo and vorinostat-treated group are shown. Tumors were isolated and tumor
weight and volume were determined. In most cases tumors were monolobular, whereas only in two mice two tumor nodules were found at
injection side. Obvious differences in tumor volumes were observed between the placebo (2304.7 mm3) versus the vorinostat-treated group
(1135.4 mm3). (c) These differences were statistically highly significant at the end of treatment (P = 0.044).
Hrzenjak et al. Molecular Cancer 2010, 9:49
http://www.molecular-cancer.com/content/9/1/49
Page 6 of 11
portions. In Fig. 3B the representative samples of two
different tumors from each group (placebo and vorino-
stat-treated, respectively) are shown. Although the stan-
dard deviation of tumor size within groups, both
placebo and treated one, was noticeable all over the
treatment duration, at the end of treatment there was a
significant difference (P = 0.044) in tumor volume
between placebo and vorinostat-treated group. The aver-
age tumor volume in untreated mice was 2304.7 mm3,
whereas in vorinostat-treated mice it was 1135.4 mm3.
This difference represented a more than 50% reduction
in comparison to the placebo group (Fig. 3C).
Vorinostat induces apoptosis in MES-SA cells in vitro and
in vivo
We also performed flow cytometric analysis of MES-SA
cells in vitro, untreated or vorinostat-treated, using
Cleaved Caspase-3 (Asp175) Antibody (Alexa Fluor® 488
Conjugate). Vorinostat-treated cells clearly showed
increased accumulation of apoptotic cells in a time
dependent manner. After 72 hours of vorinostat treat-
ment, the fraction of apoptotic cells reached 36.37%
(Fig. 4).
Hematoxylin-eosin (HE) staining showed the presence
of prominent apoptotic figures in vorinostat-treated
Figure 4 Vorinostat induces apoptosis in MES-SA cells. FACS analysis of MES-SA cells labelled with cleaved caspase-3 antibody conjugated
with Alexa Fluor® 488 showed an increased percentage of apoptotic cells in vorinostat-treated cells, correlating with treatment duration. MES-SA
cells treated with 1 μM staurosporine for 4 hours were used as a positive control. For numerical analysis two independent experiments, each
containing duplicates, were performed. Representative data are shown.
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tumors, in contrast to tumors isolated from placebo
group containing less apoptotic cells (Fig. 5A-D). Immu-
nostaining for Ki-67 proliferation marker showed no sig-
nificant differences between tumors isolated from
placebo and vorinostat-treated group. Both groups were
characterized by intense Ki-67 nuclear staining in 95%
of tumor cells, indicating a very high proliferation rate
(Fig. 5E, F), which is in accordance with the fast tumor
growth observed. Condensed chromatin was also
detected by electron microscopy in a large number of
cells in tumors isolated from vorinostat-treated mice
(Fig. 6A, B). These findings additionally indicate
increased apoptotic activity upon vorinostat treatment.
Discussion
Uterine sarcomas are very rare malignancies with poor
prognosis. Precise diagnosis is usually made late, these
tumors frequently grow highly aggressive and are resis-
tant to chemotherapy. Thus, surgical excision is often
the only treatment option [18,19]. Molecularly targeted
therapies of different tumor types showed a promising
improvement in the last few years. Histone deacetylases,
a group of enzymes responsible for epigenetic changes
of histones and some other proteins, belong to the most
promising targets. Some inhibitors of these enzymes are
already used in preclinical and clinical trials. Vorinostat
efficiently inhibits HDACs class I and II by binding to
Figure 5 H&E and Ki-67 immunostaining of tumor tissue from nude mice xenografts. (a, c) Solid aggregates of highly atypical tumor cells
showing large, round nuclei, prominent nucleoli and abundant cytoplasm were visible in tumors isolated from the placebo group. (b) In
vorinostat-treated tumors, highly atypical tumor cells associated with abundant apoptosis were seen. Areas of apoptosis (marked by arrows)
show tumor cells with smaller, dark nuclei with condensed chromatin and small rim of cytoplasm. Note the presence of vacuolated cytoplasm,
fragmented tumor cells and isolated nuclei of tumor cells. (d) Aggregate of tumor cells with an apoptotic body characterized by dense
eosinophilic cytoplasm and hyperchromatic nuclear fragments (marked by arrow). (e, f) More than 95% of tumor cells showed a positive nuclear
immunoreaction for Ki-67, both in placebo and in vorinostat-treated tumors.
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the active site of the enzyme [20]. However, vorinostat
seems to have different effects depending on the cell
line used. While in most experimental systems vorino-
stat caused apoptotic changes, there are also data show-
ing that autophagic processes are activated by vorinostat
[13,21-23]. Vorinostat has been already approved by
FDA for the therapy for cutaneous T-cell lymphoma
[24]. That makes it also an interesting candidate for the
treatment of other malignancies. However, data con-
cerning gynecological malignancies in general and uter-
ine sarcoma in particular are missing.
Here we attempted to establish a uterine sarcoma cell
model for testing vorinostat in vitro and in vivo. For this
purpose MES-SA cell line was used since it has been
shown that these cells are tumorigenic in nude mice [1].
In fact, after injecting 5 × 106 MES-SA cells into nude
mice, tumor growth has been induced with 100% effi-
ciency. Our intention was also to use this model as an
alternative for endometrial stromal sarcoma. Immuno-
histochemical comparison of MES-SA and ESS-1 cells
proved that these two cell lines are quite similar regard-
ing different cell markers.
In our experiments, both cell lines (MES-SA and ESS-
1) expressed different HDACs and responded similarly
to the treatment with vorinostat. That might make
endometrial stromal sarcomas and uterine sarcomas in
general potential candidates for treatment with vorino-
stat and/or other HDAC inhibitors. Both our in vitro
and in vivo data clearly indicate that vorinostat is able
to significantly reduce MES-SA cell-growth already after
a short treatment period and at a dose range used thera-
peutically in the clinic. Moreover, it has been shown by
others that in this concentration range vorinostat is well
tolerated and causes only minor side effects in patients
[25]. In our experiments we did not observe any patho-
logical changes in the main organs in mice, suggesting
that vorinostat may have no pronounced toxic effects
during treatment over 21-days. These data correlate well
with data from long-term studies in humans, in which
vorinostat has been used as a therapeutic agent for
cutaneous T-cell lymphoma and some other solid
tumors. Reduction of tumor volume for more than 50%
in comparison to the placebo group shows the potential
of vorinostat in the therapy of uterine sarcomas. Our
data also suggest that this reduction of tumor size is not
so much the effect of diminished tumor cell prolifera-
tion but mainly due to specific apoptotic cell death
caused by vorinostat. Descriptions of mechanisms
involved in the cell death caused by vorinostat treatment
of different cell lines are somehow contradictory and
seem to depend on the cell model used. However, it
seems obvious that apoptosis as well as autophagy play
important roles. Thus, further studies should clarify
whether one of these mechanisms excludes the other, or
whether they are somehow compensating each other
during or after vorinostat treatment.
Figure 6 Representative transmission electron microscopy of tumor tissue isolated from vorinostat-treated mouse xenografts. (a)
Shrunken nuclei with condensed and fragmented chromatin (arrow heads) in comparison to non-apoptotic nuclei (arrows). (b) Micrograph of
the boxed area of panel A at higher magnification.
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Conclusions
In summary, we showed that vorinostat efficiently killed
tumor cells and impaired the colony forming ability of
uterine sarcoma cells in vitro. It also influenced the
expression of different HDAC enzymes and p21WAF1. In
vivo experiments showed that vorinostat efficiently
inhibited tumor growth in nude mice xenografts by acti-
vating apoptosis. On the basis of these data and those
presented earlier on endometrial stromal sarcoma cells,
we conclude that vorinostat might be a promising candi-
date for therapy of patients with different types of uter-
ine sarcomas.
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